Health Technology Dr. Reddy's Laboratories Ltd. Business Summary
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Financial Highlights
Mar 2021
INR USD Revenue 189,722M 2,555.69M Gross Profit 103,077M 1,388.52M Operating income 31,977M 430.75M Income before tax 27,844M 375.07M Net income 19,149M 257.95M EBITDA 44,773M 603.12M Diluted EPS 115.14 1.55 Dividends Per Share 25 0.33 Total Assets 265,491M 3,631.20M Total liabilities 90,510M 1,237.93M Total equity 174,981M 2,393.27M Operating cash flow 35,602M 479.58M Currency in INR Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
140,809M
142,028M
153,851M
174,600M
189,722M
Gross Profit
73,531M
71,189M
78,008M
88,078M
103,077M
Operating income
12,878M
11,182M
19,584M
28,637M
31,977M
Income before tax
14,304M
13,997M
22,005M
17,471M
27,844M
Net income
12,039M
9,806M
18,795M
19,498M
19,149M
EBITDA
24,155M
22,892M
31,774M
41,109M
44,773M
Diluted EPS
72.09
59.01
113.09
117.39
115.14
Dividends Per Share
20
20
20
25
25
Total Assets
219,821M
225,604M
225,427M
232,241M
265,491M
Total liabilities
95,777M
99,144M
85,230M
77,253M
90,510M
Total equity
124,044M
126,460M
140,197M
154,988M
174,981M
Operating cash flow
21,216M
17,110M
27,878M
29,249M
35,602M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
2,099.83M
2,203.14M
2,199.67M
2,462.41M
2,555.69M
Gross Profit
1,096.54M
1,104.28M
1,115.31M
1,242.17M
1,388.52M
Operating income
192.04M
173.45M
280.00M
403.87M
430.75M
Income before tax
213.31M
217.12M
314.61M
246.39M
375.07M
Net income
179.53M
152.11M
268.71M
274.98M
257.95M
EBITDA
360.21M
355.10M
454.28M
579.76M
603.12M
Diluted EPS
1.07
0.91
1.61
1.65
1.55
Dividends Per Share
0.29
0.31
0.28
0.35
0.33
Total Assets
3,385.24M
3,459.03M
3,254.08M
3,069.88M
3,631.20M
Total liabilities
1,474.96M
1,520.10M
1,230.31M
1,021.17M
1,237.93M
Total equity
1,910.27M
1,938.92M
2,023.77M
2,048.71M
2,393.27M
Operating cash flow
316.38M
265.41M
398.58M
412.50M
479.58M
Valuation Measures
Mar 2021
PER 39.10 ROA 7.69% ROE 11.60% Operating margin 16.85% Profit margin 10.09%
Key executives
Chief Executive & Operating Officer:
Erez Israeli
Chief Financial Officer:
Parag Agarwal
Secretary & Compliance Officer:
Sandeep Poddar
Executive Vice President & Head-Branded Markets:
M. V. Ramana
Chief Human Resource Officer & Executive VP:
Archana Bhaskar Shareholders
Dr. Reddy's Holdings Ltd. (24.8%)
First Sentier Investors (Australia) IM Ltd. (3.5%)
SBI Funds Management Pvt Ltd. (2.1%)
Aditya Birla Sun Life Amc Ltd. (Investment Management) (1.9%)
BlackRock Fund Advisors (1.8%)
GIC Pte Ltd. (Investment Management) (1.6%)
Life Insurance Corp of India (1.5%)
The Vanguard Group, Inc. (1.4%)
Mirae Asset Global Investments (India) Pvt Ltd. (1.4%)
ICICI Prudential Life Insurance Co. Ltd. (Invt Port) (1.3%)
Contact Details Website: http://www.drreddys.com Address:
Door No. 8-2-337,
Road No. 3,
Hyderabad,
500034,
India
Phone:
+91.40.49002900
Related Companies
Dr. Reddy's Farmaceutica do Brasil Ltda.
Dr. Reddy's Employees ESOS Trust
Dr. Reddy's Research Foundation
BMS Laboratories Ltd.
Wockhardt Ltd. /Domestic Formulations Bus/
Imperial Credit Pvt Ltd.
Ducere Pharma LLC/Otc Bus/
UCB SA /Established Product Bus/
Dr. Reddy's Laboratories SA
Zenovus Biotech Pvt Ltd.
Regkinetics Services Ltd.
Dr. Reddy's Bio-Sciences Ltd.
Idea2Enterprises (India) Pvt Ltd.
Industrias Quimicas Falcon de Mexico SA de CV
Kunshan Rotam Reddy Pharmaceutical Co., Ltd.
Aurigene Discovery Technologies Ltd.
Perlecan Pharma Pvt Ltd.
Macred India Pvt Ltd.
BASF SE /Pharmaceutical Contract Manufacturing Unit/
Dowpharma /Small Molecules Business/
Laboratorios Litaphar SA
F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
Trigenesis Therapeutics, Inc.
OctoPlus N.V.
Competitors
Perrigo Co. Plc
KRKA dd
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Limited
Glenmark Pharmaceuticals Limited
Hikma Pharmaceuticals Plc
Takeda Pharmaceutical Co. Ltd.
Bayer AG
Pfizer Limited
Sanofi
Lupin Limited
Cipla Limited
Alkem Laboratories Ltd.
Fresenius SE & Co. KGaA
Nichi-Iko Pharmaceutical Co., Ltd.
Cadila Healthcare Limited
Chemical Works of Gedeon Richter Plc
STADA Arzneimittel AG
Sanofi India Limited
Viatris, Inc.
GlaxoSmithKline Pharmaceuticals Limited
Sun Pharmaceutical Industries Limited
Piramal Enterprises Ltd.
Abbott India Limited
Endo International Plc
Hindustan Unilever Limited
Lonza Group AG
Aurobindo Pharma Ltd
Dishman Carbogen Amcis Ltd.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 18 Jun, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
